de Oliveira, L.L.H.; de Assis, A.C.R.; Giraldez, V.Z.R.; Scudeler, T.L.; Soares, P.R. Dyslipidemia: A Narrative Review on Pharmacotherapy. Pharmaceuticals2024, 17, 289.
de Oliveira, L.L.H.; de Assis, A.C.R.; Giraldez, V.Z.R.; Scudeler, T.L.; Soares, P.R. Dyslipidemia: A Narrative Review on Pharmacotherapy. Pharmaceuticals 2024, 17, 289.
de Oliveira, L.L.H.; de Assis, A.C.R.; Giraldez, V.Z.R.; Scudeler, T.L.; Soares, P.R. Dyslipidemia: A Narrative Review on Pharmacotherapy. Pharmaceuticals2024, 17, 289.
de Oliveira, L.L.H.; de Assis, A.C.R.; Giraldez, V.Z.R.; Scudeler, T.L.; Soares, P.R. Dyslipidemia: A Narrative Review on Pharmacotherapy. Pharmaceuticals 2024, 17, 289.
Abstract
Hypercholesterolemia plays a fundamental role in the development and progression of atherosclerosis. Current guidelines for treating dyslipidemia target low-density lipoprotein-cholesterol (LDL-C). Despite advances in the pharmacotherapy of atherosclerosis, the most successful agents used to treat this disease – statins – remain insufficient in the primary or secondary prevention of acute myocardial infarction. Advancing therapy for hypercholesterolemia with emerging new drugs, either as monotherapy or in combination, is expected to improve cardiovascular outcomes.
Keywords
dyslipidemias; cholesterol; statins; gene therapy
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
